Key result
ALPK3 gene therapy reverses cardiomyopathy in mice and restores contractile function in human cardiac organoids.
Why the study?
Loss-of-function variants of ALPK3 cause severe forms of cardiomyopathy with no curative treatment.
Does ALPK3 gene addition restore contractile function and reverse disease in preclinical models of ALPK3 and TTN-truncation cardiomyopathy?
Does ALPK3 gene addition restore contractile function and reverse disease in preclinical models of ALPK3 and TTN-truncation cardiomyopathy?
ALPK3 gene addition shows promise as a therapeutic strategy for severe cardiomyopathies caused by ALPK3 loss-of-function or TTN-truncation variants in preclinical models.
Answers are grounded in this paper and cite their sources.
ALPK3 gene therapy merits human trials in genetic cardiomyopathy; leaves open translation from mice and organoids to patients.
Loss-of-function variants of ALPK3 can cause severe forms of cardiomyopathy with no curative treatment. A therapy that delivers full-length ALPK3 prevents and even reverses disease in mice, restores contractile function in human cardiac organoids, and rescues impaired contraction in an organoid model of TTN-truncation cardiomyopathy.
No takes yet. Share an insight, caveat, or question.
Grünewald et al. (2026) studied this question. Gene therapy delivering full-length ALPK3 prevents and reverses cardiomyopathy in mice and restores contractile function in human cardiac organoids, including TTN-truncation models.
Synapse has enriched 10 related papers. Consider them for comparative context: